Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (4) Autor Chamone,D.A.F. (4) Dorlhiac-Llacer,P.E. (2) Pereira,J. (2) Azevedo,M.C. (1) Beitler,B. (1) Buccheri,V. (1) Bydlowski,S.P. (1) Carneiro,R.C.G. (1) Chaoubah,A. (1) Dulley,F.L. (1) Giampaoli,V. (1) Godoy,C.R.T. (1) Hallack Neto,A.E. (1) Levy,D. (1) Llacer,P.D. (1) Macedo,M.C.M.A. (1) Maranhão,R.C. (1) Marquezini,M.V. (1) Toffoletto,O. (1) Velloso,E.D.R.P. (1) Mais... Palavra-chave Acute myelogenous leukemia (1) Acute myeloid leukemia (1) Angiogenesis (1) CHOP lymphoma treatment (1) Chemotherapy (1) Chronic myeloid leukemia (1) Circulating endothelial cells (1) Consolidation therapy (1) Cytotoxicity (1) Daunorubicin (1) Diffuse large B-cell lymphoma (1) Flow cytometry (1) High-dose cytarabine (1) LDE complex (1) Low-density lipoprotein (1) ProMACE-CytaBOM treatment (1) Prognosis (1) RT-PCR (1) Vascular endothelial growth factor (1) Mais... Tipo do documento Info:eu-repo/semantics/article (4) Ano 2015 (2) 2006 (1) 2001 (1) País Brazil (4) Idioma Inglês (4)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 4 Primeira ... 1 ... Última Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis BJMBR Godoy,C.R.T.; Levy,D.; Giampaoli,V.; Chamone,D.A.F.; Bydlowski,S.P.; Pereira,J.. We measured circulating endothelial precursor cells (EPCs), activated circulating endothelial cells (aCECs), and mature circulating endothelial cells (mCECs) using four-color multiparametric flow cytometry in the peripheral blood of 84 chronic myeloid leukemia (CML) patients and 65 healthy controls; and vascular endothelial growth factor (VEGF) by quantitative real-time PCR in 50 CML patients and 32 healthy controls. Because of an increase in mCECs, the median percentage of CECs in CML blast crisis (0.0146%) was significantly higher than in healthy subjects (0.0059%, P<0.01) and in the accelerated phase (0.0059%, P=0.01). There were no significant differences in the percentages of CECs in chronic- or active-phase patients and healthy subjects... Tipo: Info:eu-repo/semantics/article Palavras-chave: Circulating endothelial cells; Vascular endothelial growth factor; Chronic myeloid leukemia; Flow cytometry; Angiogenesis. Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000600509 In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells BJMBR Dorlhiac-Llacer,P.E.; Marquezini,M.V.; Toffoletto,O.; Carneiro,R.C.G.; Maranhão,R.C.; Chamone,D.A.F.. Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7% of blast cells and 20.2% of normal bone marrow cells (P<0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these drugs to... Tipo: Info:eu-repo/semantics/article Palavras-chave: Cytotoxicity; Acute myelogenous leukemia; Daunorubicin; Low-density lipoprotein; LDE complex; RT-PCR. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001000004 Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia BJMBR Azevedo,M.C.; Velloso,E.D.R.P.; Buccheri,V.; Chamone,D.A.F.; Dorlhiac-Llacer,P.E.. In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received <1.5 g/m2 every 12 h on 3... Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; Chemotherapy; Consolidation therapy; High-dose cytarabine; Prognosis. Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200178 Results of CHOP chemotherapy for diffuse large B-cell lymphoma BJMBR Hallack Neto,A.E.; Pereira,J.; Beitler,B.; Chamone,D.A.F.; Llacer,P.D.; Dulley,F.L.; Macedo,M.C.M.A.; Chaoubah,A.. Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the... Tipo: Info:eu-repo/semantics/article Palavras-chave: Diffuse large B-cell lymphoma; CHOP lymphoma treatment; ProMACE-CytaBOM treatment. Ano: 2006 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007 Registros recuperados: 4 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco